Ovarian carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant neoplasm originating from the surface ovarian epithelium. It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women. It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups. Adenocarcinomas constitute the vast majority of ovarian carcinomas. The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type. The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver. Lung and pleura are the most common sites of extra-abdominal spread. The primary form of therapy is surgical. The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms. --2002
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Ovarian carcinoma
- Therapeutic area
- Oncology
- ovarian carcinoma
- Advanced Epithelial Ovarian Cancer
- Advanced Ovarian Carcinoma
- carcinoma of ovary
- carcinoma of the ovary
- epithelial ovarian cancer
- Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
- Locally Advanced Ovarian Carcinoma
- Metastatic Epithelial Ovarian Cancer
- Metastatic Ovarian Carcinoma
- Ovarian Carcinoma, Recurrent
- Ovarian Carcinoma, Stage 3 or 4
- ovary carcinoma
- Recurrent Carcinoma of Ovary
- Recurrent Epithelial Ovarian Cancer
- Recurrent Ovarian Carcinoma
- Recurrent, Epithelial Ovarian Cancer
- Refractory Ovarian Carcinoma
- Relapsed Epithelial Ovarian Cancer
- Stage III Ovarian Carcinoma
- Stage IIIB Ovarian Carcinoma
- Stage IV Ovarian Carcinoma
- Unresectable Ovarian Carcinoma
- ovarian cancer
- ovarian epithelial cancer
- Severity
- Terminal
- Endocrinology
- Oncology
- Reproductive Health
Sources for recorded values
- MONDO ID
- MONDO:0005140
- Parent condition
- MONDO:0018364
Related records
Broader conditions (23)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine system disorder
- Epithelial neoplasm
- Female reproductive organ cancer
- Female reproductive system disorder
- Female reproductive system neoplasm
- Gonadal disorder
- Human disease
- Malignant epithelial tumor of ovary
- Neoplasm
- Neoplastic disease or syndrome
- Ovarian cancer
- Ovarian disorder
- Ovarian epithelial tumor
- Ovarian neoplasm
Narrower conditions (25)
- Familial ovarian carcinoma
- Hypercalcemic type ovarian small cell carcinoma
- Krukenberg carcinoma
- Low-grade serous ovarian carcinoma
- Ovarian adenocarcinoma
- Ovarian carcinosarcoma
- Ovarian clear cell adenocarcinoma
- Ovarian clear cell cystadenocarcinoma
- Ovarian cystadenocarcinoma
- Ovarian endometrioid adenocarcinoma
- Ovarian endometrioid adenocarcinoma with squamous differentiation
- Ovarian large-cell neuroendocrine carcinoma
- Ovarian mucinous adenocarcinoma
- Ovarian mucinous cystadenocarcinoma
- Ovarian seromucinous carcinoma
- Ovarian serous adenocarcinoma
- Ovarian serous cystadenocarcinoma
- Ovarian serous surface papillary adenocarcinoma
- Ovarian small cell carcinoma
- Ovarian squamous cell carcinoma
Trials (992)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- 11C Topotecan PET Imaging
- 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
- 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
- 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings
- 68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- A Beta-only IL-2 ImmunoTherapY Study
- A Biomarker Screening Protocol for Participants With Solid Tumors
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
- A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
- A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
- A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
- A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Approved drugs (9)
- Bevacizumab
- Carboplatin
- Doxorubicin hydrochloride
- Gemcitabine hydrochloride
- Niraparib tosylate monohydrate
- Olaparib
- Paclitaxel
- Rucaparib camsylate
- Trabectedin
Drugs in development (300)
- 2-methoxyestradiol Phase 2
- 9-aminocamptothecin Phase 2
- Abagovomab Phase 1
- Abemaciclib Phase 1
- Acetylcysteine Phase 1
- Adagloxad simolenin Phase 2
- Adavosertib Phase 2
- Aflibercept Phase 1
- Aldesleukin Phase 2
- Alisertib Phase 2
- Alpelisib Phase 2
- Alvocidib Phase 2
- Alvocidib hydrochloride Phase 2
- Amifostine Phase 1
- Ascorbic acid Phase 2
- Aspirin Phase 1
- Atezolizumab Phase 3
- Atrasentan Phase 2
- Atrasentan hydrochloride Phase 2
- Auranofin Phase 2
Other linked drugs (4)
- Camrelizumab
- Daphnetin
- Parpi
- Rivoceranib mesylate